A Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine

Wells, Nicholas; Hettiarachchi, J.; Drummond, Michael; Carter, David; Parpia, Tamiza; Pang, Francis

doi:10.1046/j.1524-4733.2003.64238.x

Cited by 21 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of fourteen CEA or CUA studies were identified. Of these, six were conducted in the United States, 15-21 four in the United Kingdom, [22][23][24][25] three in Canada, 21, 26,27 and one in Belgium 28 (Table 1). A substantial amount of literature since the 1990s has been devoted to the investigation of the economic burden of migraines in different countries during recent decades.…”

Section: Economic Analyses For Migrainementioning

confidence: 99%

“…As illustrated in Table 1, several studies focusing on only a few types of triptans have had the advantage of using controlled clinical trial studies to obtain the efficacy and resource use data. 16,[22][23][24] However, those studies that compared all types of triptans available in the market have used the data from the metaanalysis 36 due to the lack of comparative clinical trial studies of all triptans. The meta-analysis study conducted by Ferrari et al 36 used raw patient data provided by the trial investigators or sponsors and so included only those clinical trials of triptan therapies with similar design and similar patient population.…”

Section: Source Of Datamentioning

confidence: 99%

See 1 more Smart Citation

Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature

Goodman

Oderda

2009

Journal of Pain & Palliative Care Pharmacotherapy

View full text Add to dashboard Cite

This paper reviews the economic evaluation literature on pharmacotherapy for migraine and identifies important trends and gaps in the literature. Given the tremendous economic burden of migraine and the availability of various therapies for migraine treatment, economic evaluation of alternative therapies plays a critical role in identifying the most cost-effective therapy to optimize health care resource allocation and clinical decisions. Particularly, physicians and clinical administrators are expected to take an active role in resource allocation decisions at the clinical level. Thus, it is important for them to be familiar with the economic evaluation in migraine pain management, and most importantly, methodologies of economic analyses and the associated shortcomings of published estimates. In this paper, the methodological characteristics of these studies are examined and their results are compared and interpreted. Alternative treatment and health outcome measures are defined and data sources described while methods for assessing the direct and indirect costs are explored. Directions for future research are identified and discussed.

show abstract

Section: Economic Analyses For Migrainementioning

confidence: 99%

Section: Source Of Datamentioning

confidence: 99%

Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature

Goodman

Oderda

2009

Journal of Pain & Palliative Care Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Triptans in general have shown to be cost effective in reducing this burden [41]. In one study, the cost for migraine attack was lower for eletriptan compared with sumatriptan [42]. Eletriptan has been shown to be associated with a > 50% reduction in time loss compared with placebo [43].…”

Section: Pharmacoeconomical Aspectsmentioning

confidence: 99%

Eletriptan review

Färkkilä¹,

Kallela²

2005

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Eletriptan is a selective, high affinity serotonin 5-HT(1B/1D)-receptor agonist which is rapidly absorbed and has a long half-life in plasma. Eletriptan has been shown to be effective and well tolerated in randomised, double-blind, placebo-controlled acute migraine trials and long-term open-label trials. Eletriptan maintains a consistency of response across three attacks and patients continue to respond to eletriptan for at least up to 1 year. Eletriptan has been compared with sumatriptan, zolmitriptan, naratriptan and ergotamine/caffeine in placebo-controlled, randomised, head-to-head trials, and has shown better efficacy with similar adverse events. In a large triptan meta-analysis, including 53 trials and > 24,000 patients, eletriptan 80 mg showed better efficacy, similar consistency but lower tolerability compared with sumatriptan 100 mg. Eletriptan has also shown efficacy in difficult-to-treat patients who were dissatisfied with their previous treatment with sumatriptan, rizatriptan, nonsteroidal anti-inflammatory drugs or Excedrin.

show abstract

“…The difference is that between efficacy and real clinical effectiveness. For example, a study reported success in 64-67% for eletriptan vs. 50-53% sumatriptan for the first "efficacy" outcome described above, but only 16-17% vs. 14-16% for the second more rigorous "effectiveness" outcome [7]. For a health economic study, the really useful clinical outcome is what is required.…”

Section: Intangiblementioning

confidence: 99%

“…For example, one study looked at eletriptan vs. sumatriptan using the more complex outcome measure described above [7]. Another used another composite endpoint of sustained freedom from pain and no adverse effects to compare almotriptan and sumatriptan [12].…”

Section: Cost Effectiveness Analysismentioning

confidence: 99%

Pharmacoeconomics for migraine and headache researchers: basic concepts, methods and terminology

Walley

2004

J Headache Pain

View full text Add to dashboard Cite

Pharmacoeconomics, the application of health economics to pharmaceuticals, is an increasingly important part of the evaluation of any therapy. It is a response to limitations on the resources available for medical care, and the need to justify how we spend these resources for the public good. This review summarises some of the key issues in pharmacoeconomics, drawing examples from the literature on migraine or headaches. It describes how pharmacoeconomics is fundamentally comparative, and must be based on real world practice rather than on clinical trials. An important point is what outcomes in migraine might be used in such studies. The types of studies commonly encountered are detailed. These examples illustrate some of the limitations of the process: a risk of industry driven bias, and a draw of money into the areas evaluated (e. g., acute therapies) rather than those not considered (e. g., longterm therapies).

show abstract

A Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine

Abstract: Further refinement of outcomes measurement in migraine would be valuable and eletriptan has a potentially important role to play in the cost-effective management of the disorder.

Cited by 21 publications

References 22 publications

Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature

Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature

Eletriptan review

Pharmacoeconomics for migraine and headache researchers: basic concepts, methods and terminology

Contact Info

Product

Resources

About